Skip to Main Content

INFORMATION FOR

Hari Deshpande, MD

Associate Professor of Medicine (Medical Oncology); Disease Aligned Research Team (DART) Leader Sarcoma, Medical Oncology; Director Medical Oncology Inpatient Consult Service, Medical Oncology

Contact Information

Hari Deshpande, MD

Research Summary

I have been involved in clinical trials since joining Yale in 2004. My main interests are in sarcoma, thyroid cancers and cancers of unknown primary. I was named leader of the Sarcoma DART (Disease aligned research team) on January 1st 2022. My current research includes new treatments for thyroid cancers as well as all types of sarcoma. I am fortunate to have been an investigator in over 20 trials of different therapies in Sarcomas, head and neck cancers, thyroid cancers and GU cancers

Extensive Research Description

I have been involved in research at the Yale Cancer Center since 2004. Initially, my practice included patients with GU and head and neck cancers. However, since 2010, I have mainly seen patients with sarcomas, thyroid cancer, and cancers of unknown primary. I was recently named the Disease Aligned Research Team (DART) leader for sarcoma in 2022. Sarcomas are a rare type of cancer. Of the almost 2 million new cases of cancer that we see today, sarcomas account for less than 20,000. Furthermore, they are subdivided not only in bone and soft tissue types, but also into more than 50 subtypes within these categories. This makes learning and understanding the disease more difficult as many clinicians may not see large numbers of these patients. I have been very fortunate to work at Yale which is a referral center for patients with sarcoma. My colleagues in surgical oncology treat soft tissue sarcomas involving the abdominal cavity and other sites, as well as orthopedic oncology surgeons who treat patients with bone and soft tissue sarcomas of the extremities, have national and international reputations that have brought patients to Smilow. This has allowed us to participate in clinical trials as we have the patient population you may be able to take advantage and enroll in studies of new treatment modalities.

My main focus of research is in clinical trials. These have been either investigator initiated, industry sponsored, or cooperative group. I have been fortunate to be able to work with excellent physicians and scientists in other specialties who have helped design innovative studies for our patients. One trial that I was the local principal investigator for, had a larger accrual at Yale than many other larger cancer centers. This involved patients with desmoid tumors, a rare type of soft tissue tumor that can often cause significant morbidity and is relatively unknown to many clinicians. This trial, a cooperative group study involving sorafenib, and another industry sponsored study that was open at Smilow involving nirogecastat, have shown great promise and may give patients options for treatment that do not involve major surgery. Because desmoid tumors and many sarcomas are rare cancers or tumors, these types of clinical trials require cooperation among major cancer centers around the country and around the world. It is a great honor to be involved in this type of collaboration, to work with and hear reports from colleagues in different institutions and have access to potentially new treatment options for our patients. Other rare tumors that we have had trials for include tenosynovial giant cell tumor (TGCT) and PEComas.

Another trial that accrued very well at Yale was one I participated in, in collaboration with my colleagues from endocrine surgery. This helped established a new treatment for medullary thyroid cancer vandetanib.

More recently I've been involved in trials for patients with de- differentiated liposarcoma, myxoid liposarcoma, differentiated thyroid cancer, chondrosarcoma and angiosarcoma. As the DART leader I hope to bring many other clinical trials to Yale, to help patients with both sarcoma and thyroid cancers.

The clinical trials I am involved with change frequently - I encourage interested people to view the Yale Cancer Center Clinical Trials website. http://yalecancercenter.org/patient/trials/

Sarcoma; Cancers of unknown primary; Thyroid cancer

Coauthors

Research Interests

Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Soft Tissue Neoplasms; Sarcoma, Synovial; Thyroid Neoplasms; Neoplasms, Connective and Soft Tissue; Liposarcoma, Myxoid

Selected Publications

  • P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).Schuetze S, Ballman K, Ganjoo K, Davis E, Morgan J, Tinoco G, Burgess M, Van Tine B, Choy E, Shepard D, Kelly C, Riedel R, von Mehren M, Siontis B, Attia S, Schwartz G, Deshpande H, Kozlowski E, Chen H, Rubin B. P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE). Journal Of Clinical Oncology 2021, 39: 11503-11503. DOI: 10.1200/jco.2021.39.15_suppl.11503.
  • Renal sarcomas: Epidemiology, treatment and outcomes.Uhlig J, Uhlig A, Deshpande H, Hurwitz M, Humphrey P, Kim K. Renal sarcomas: Epidemiology, treatment and outcomes. Journal Of Clinical Oncology 2021, 39: 362-362. DOI: 10.1200/jco.2021.39.6_suppl.362.
  • Predictors of Lymph Node Involvement by Soft Tissue Sarcoma: An Analysis of the National Cancer Database (NCDB)Miccio J, Jairam V, Gao S, Augustyn A, Oladeru O, Onderdonk B, Costa J, Han D, Khan S, Friedlaender G, Lindskog D, Deshpande H, Tara H, Osborn H, Roberts K, Patel K. Predictors of Lymph Node Involvement by Soft Tissue Sarcoma: An Analysis of the National Cancer Database (NCDB) International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e335. DOI: 10.1016/j.ijrobp.2018.07.1028.
  • Adjuvant External Beam Radiation Therapy for Surgically Resected, Non-Metastatic Anaplastic Thyroid CancerSaeed N, Kelly J, Deshpande H, Bhatia A, Burtness B, Judson B, Mehra S, Osborn H, Yarbrough W, Peter P, Holt E, Decker R, Husain Z, Park H. Adjuvant External Beam Radiation Therapy for Surgically Resected, Non-Metastatic Anaplastic Thyroid Cancer International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e290-e291. DOI: 10.1016/j.ijrobp.2018.07.923.
  • Genetic variants including microsatellite instability in metastatic Hürthle cell carcinoma of the thyroid.Hale-Wallace N, Deshpande H, Holt E, Callender G, Gibson C, Lee G, Carling T, Ho A, Eder J, Finberg K. Genetic variants including microsatellite instability in metastatic Hürthle cell carcinoma of the thyroid. Journal Of Clinical Oncology 2018, 36: e18110-e18110. DOI: 10.1200/jco.2018.36.15_suppl.e18110.
  • Hypothyroidism to predict for long term survival in patients with fosbretabulin treated anaplastic thyroid carcinoma.Doroshow D, Deshpande H, Remick S, Bhatia A. Hypothyroidism to predict for long term survival in patients with fosbretabulin treated anaplastic thyroid carcinoma. Journal Of Clinical Oncology 2018, 36: e18108-e18108. DOI: 10.1200/jco.2018.36.15_suppl.e18108.
  • Establishment of a medical student elective on the oncology consult service using the seven principles of teaching.Deshpande H, Stein S. Establishment of a medical student elective on the oncology consult service using the seven principles of teaching. Journal Of Clinical Oncology 2018, 36: tps11021-tps11021. DOI: 10.1200/jco.2018.36.15_suppl.tps11021.
  • Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).Gounder M, Mahoney M, Van Tine B, Ravi V, Attia S, Deshpande H, Gupta A, Milhem M, Conry R, Movva S, Pishvaian M, Crawford J, Sabagh T, Maki R, Tap W, Lefkowitz R, Agaram N, Wright J, Dueck A, Schwartz G. Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105). Journal Of Clinical Oncology 2018, 36: 11500-11500. DOI: 10.1200/jco.2018.36.15_suppl.11500.
  • Advanced and metastatic soft tissue sarcoma, a review of aajcc 8th edition staging and the use of olaratumab.Deshpande H, Pathak R, Riaz F. Advanced and metastatic soft tissue sarcoma, a review of aajcc 8th edition staging and the use of olaratumab. 2018, 01 DOI: 10.35841/cancer-immunology.1.1.17-23.
  • Response to nivolumab in radiation induced, BRCA-2 N372H variant, programed death ligand-1 negative, pleomorphic undifferentiated sarcoma.Foster Y, Cecchini M, Slater D, Neumeister V, Walther Z, Husain Z, Judson B, Deshpande H. Response to nivolumab in radiation induced, BRCA-2 N372H variant, programed death ligand-1 negative, pleomorphic undifferentiated sarcoma. Journal Of Clinical Oncology 2017, 35: 61-61. DOI: 10.1200/jco.2017.35.7_suppl.61.
  • A retrospective analysis to assess the validity of multidisciplinary tumor boards using a new tool: The Subspecialty Academic Multidisciplinary Tumor Board score (SAMTB).Deshpande H, Hurwitz M, Cecchini M, Ciarleglio M, Deng Y, Li F, Sherwood M, Petrylak D. A retrospective analysis to assess the validity of multidisciplinary tumor boards using a new tool: The Subspecialty Academic Multidisciplinary Tumor Board score (SAMTB). Journal Of Clinical Oncology 2016, 34: e18188-e18188. DOI: 10.1200/jco.2016.34.15_suppl.e18188.
  • Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment.Kim J, Kang Y, Shin M, Deshpande H, Hurwitz M, Roberts J, Cardinale J, Narayana A, Kang I, Petrylak D. Changes in T cell immunity in patients with metastatic castration resistant prostate treated with Radium-223 treatment. Journal Of Clinical Oncology 2016, 34: 295-295. DOI: 10.1200/jco.2016.34.2_suppl.295.
  • Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014.Flaig T, Tangen C, Hussain M, Agarwal N, Mitsiades N, Deshpande H, Vaishampayan U, Thompson I. Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014. Journal Of Clinical Oncology 2015, 33: 152-152. DOI: 10.1200/jco.2015.33.7_suppl.152.
  • Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.Bastholt L, Brose M, Jarzab B, Schlumberger M, Siena S, De La Fouchardiere C, Paschke R, Deshpande H, Shi Y, Elisei R, Gao M, Li L, Prins K, Walker H, Mitchell D, Lettieri J, Molnar I, Kappeler C, Pena C. Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial. Journal Of Clinical Oncology 2014, 32: 6061-6061. DOI: 10.1200/jco.2014.32.15_suppl.6061.
  • Outcomes for stage IVA squamous cell carcinoma of the oral cavity according to staging subtypes.Marrone K, Otremba M, Groisberg R, Deshpande H, Crawford F, Acevedo-Gadea C, Gould Rothberg B, Judson B, Morgensztern D. Outcomes for stage IVA squamous cell carcinoma of the oral cavity according to staging subtypes. Journal Of Clinical Oncology 2013, 31: 6076-6076. DOI: 10.1200/jco.2013.31.15_suppl.6076.
  • Vandetanib for aggressive and symptomatic medullary thyroid cancerDeshpande H, Carling T, Khan N, Holt E. Vandetanib for aggressive and symptomatic medullary thyroid cancer Journal Of Clinical Practice 2013, 10: 275-282. DOI: 10.2217/cpr.13.17.
  • Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx.Acevedo-Gadea C, Baumgart M, Wang Z, Deshpande H, Davies M, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2012, 30: 5529-5529. DOI: 10.1200/jco.2012.30.15_suppl.5529.
  • Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck.Baumgart M, Acevedo-Gadea C, Wang Z, Buta E, Davies M, Deshpande H, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2012, 30: 5532-5532. DOI: 10.1200/jco.2012.30.15_suppl.5532.
  • Medullary thyroid cancer in the past, present and future: from bench to bedsideDeshpande H, Morgensztern D, Sosa J. Medullary thyroid cancer in the past, present and future: from bench to bedside Expert Review Of Endocrinology & Metabolism 2011, 6: 585-597. DOI: 10.1586/eem.11.44.
  • Research HighlightsDeshpande H, Sosa J. Research Highlights Personalized Medicine 2010, 7: 617-619. DOI: 10.2217/pme.10.67.
  • A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P).Abu-Khalaf M, Gettinger S, Trieu V, Deshpande H, DiGiovanna M, Azodi M, Desai N, Kelly W, Schwartz P, Harris L. A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P). Journal Of Clinical Oncology 2010, 28: 2534-2534. DOI: 10.1200/jco.2010.28.15_suppl.2534.
  • Accelerated Hypofractionated Radiation vs. Standard Fractionated Radiation Concurrent with Cetuximab Chemotherapy in Locally Advanced Head and Neck Cancer (LAHNC)Galper S, Deshpande H, Rose M, Colasanto J, Decker R. Accelerated Hypofractionated Radiation vs. Standard Fractionated Radiation Concurrent with Cetuximab Chemotherapy in Locally Advanced Head and Neck Cancer (LAHNC) International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s433-s434. DOI: 10.1016/j.ijrobp.2009.07.992.
  • Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC)Galper S, Deshpande H, Rose M, Decker R. Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC) Journal Of Clinical Oncology 2009, 27: e17030-e17030. DOI: 10.1200/jco.2009.27.15_suppl.e17030.
  • A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumorsDeshpande H, Gettinger S, Rowen E, Abu-Khalaf M, Clarke J, Burns A, Kelly W. A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors Journal Of Clinical Oncology 2009, 27: e13501-e13501. DOI: 10.1200/jco.2009.27.15_suppl.e13501.

Clinical Trials

ConditionsStudy Title
Larynx; Lip, Oral Cavity and PharynxThe BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ProstateA Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
ProstateRandomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer
Larynx; Lip, Oral Cavity and PharynxA Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Larynx; Lip, Oral Cavity and PharynxA Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
ProstateSIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer
ProstateA Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer
Larynx; Lip, Oral Cavity and PharynxA Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)
PediatricsPrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
Corpus Uteri; Larynx; Lung; Soft Tissue; Unknown SitesA Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Thyroid; Phase IA Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
ProstatePhase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Urinary BladderPhase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)
ProstatePhase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Esophagus; Larynx; Lip, Oral Cavity and PharynxA Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
ProstatePhase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer
Other SkinA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Prostate; Phase IA Phase 1, Open-label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer Who Have Progressed on at Least Two Prior Systemic Therapies.
Bones and Joints; Kidney; Soft Tissue; PediatricsPhase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumors
Other Urinary; Urinary BladderPhase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy